Search

Displaying results 3241 - 3250 of 10000 in total
  1. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

  2. Drug

    Pimethixene

    go.drugbank.com/drugs/DB13292
    Approved

    Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. It is an anticholinergic used in the treatment of bronchitis.

  3. Drug

    Colestilan chloride

    go.drugbank.com/drugs/DB11634
    ApprovedWithdrawn

    Colestilan is an ingredient in the EMA-withdrawn product BindRen.

  4. Drug

    Nomegestrol

    go.drugbank.com/drugs/DB11636
    Approved

    Nomegestrol is an ingredient in the EMA-authorised product Zoely.

  5. Drug

    Formic acid

    go.drugbank.com/drugs/DB01942
    ApprovedInvestigational

    It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. … It is commonly used as a preservative and antibacterial agent in livestock feed.

  6. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    an aromatic nucleus in the presence of other aromatically bonded functional groups. … Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

  7. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    Hyperpolarized Xenon-129 (Xe-129) is a contrast agent used in the lung's clinical magnetic resonance imaging (MRI). … [A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.

  8. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  9. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  10. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.